Please login to the form below

Not currently logged in
Email:
Password:

drug side effects

This page shows the latest drug side effects news and features for those working in and with pharma, biotech and healthcare.

Tecfidera successor’s side-effect profile boosts Biogen

Tecfidera successor’s side-effect profile boosts Biogen

One of the biggest issues is that these newer treatments don’t cause the gastrointestinal side-effects frequently seen in patients taking Tecfidera. ... However, that’s not to say patients on the new drug were without side-effects: the most common

Latest news

  • ViiV builds case for switching to its two-drug HIV combinations ViiV builds case for switching to its two-drug HIV combinations

    The TANGO study is intended to show that people with HIV can reduce the number of medicines in their HIV treatment regimen, potentially reducing the risk of side effects and drug ... Injectable option. Meanwhile, ViiV also had an update this week on

  • ViiV bags EU okay for new two-drug HIV therapy ViiV bags EU okay for new two-drug HIV therapy

    It claims the two-drug regimens can reduce drug exposure and side effects, as well as improve adherence to therapy while maintaining the same level of efficacy. ... efficacy is non-inferior to a three-drug regimen whilst containing fewer

  • Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

    Other side effects including nausea, vomiting and fever were seen in four of the six patients. ... In three of the children, nausea/vomiting could be controlled with oral anti-emetic drugs, but in one case the side effects were so bad the patient had to

  • CHMP nod for Alexion, GSK drugs, revocation for Lartruvo CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

    By giving patients a simpler regimen containing fewer drugs, the expectation is that long term management of the condition will be easier, with patients less likely to develop side-effects. ... The drug is a vital new weapon for the company in its

  • AbbVie enters BCMA race with Teneobio deal AbbVie enters BCMA race with Teneobio deal

    of CAR-Ts, they could emerge as the new standard of care, not having the complicated and expensive manufacturing process with the cell therapies, and also potentially producing fewer side-effects. ... Teneobio’s drug development platform TeneoSeek

More from news
Approximately 1 fully matching, plus 104 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Much of this research centred on improving the selectivity of compounds so that they hit the target, M1, without also interacting with similar receptors linked to the intolerable side effects. ... Meanwhile, Karuna Pharmaceuticals has raised $42m to

  • Redirecting your patient strategy Redirecting your patient strategy

    But when people are dealing with their condition for so long, it is important that you understand how they're actually managing it, how they're using the drug.”. ... These new companies have developed novel business models based on sharing the data and

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    IIs are more potent, with fewer side effects and drug interactions and the top reason for prescribing them is their good tolerability profile. ... As patients differ so do their barriers to adherence, whether this be complexity of the dosing regimen,

  • Patients First Patients First

    to their thoughts on the impact of drug side effects, these are all areas that pharma is already actively engaged with at some level.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    The G-BA assesses drugs on four criteria: mortality; morbidity (for example, symptom improvement); quality of life; and adverse events (toxicity and side effects). . ... A natural question to ask is how the benefit finding impacts the final price of a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • My MS journey: one patient's search for innovation

    I’ve also seen a neuro-urologist who deals with bladder problems. The problem is, each specialist may give you a drug which can have unpleasant side effects, causing another layer

  • What does social media listening actually tell us?

    They have experiences, opinions and ideas which could be used to improve both treatments and practices (such as reports of side effects and effective drug combinations, for example) – and the methods ... The limits and regulations which accompany the

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics